World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 26 October 2021
Main ID:  NCT03227263
Date of registration: 21/07/2017
Prospective Registration: Yes
Primary sponsor: Hospices Civils de Lyon
Public title: BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT). BABH
Scientific title: BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT). A National, Multicenter Phase III Study
Date of first enrolment: September 28, 2017
Target sample size: 24
Recruitment status: Completed
URL:  https://clinicaltrials.gov/show/NCT03227263
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).  
Phase:  Phase 3
Countries of recruitment
France
Contacts
Name:     DUPUIS-GIROD, MD
Address: 
Telephone:
Email:
Affiliation:  Hospices Civils de Lyon
Key inclusion & exclusion criteria

Inclusion Criteria:

- Age = 18 years.

- Patients who have given their free informed and signed consent.

- Patients affiliated to a social security scheme or similar.

- Patients monitored for clinically confirmed HHT (presence of at least three Curaçao
criteria) and / or with molecular biology confirmation.

- Blood transfusions with the requirement for at least 4 units of blood in the 3-month
period before study enrollment, related to epistaxis or digestive bleeding.

Exclusion Criteria:

- Women who are pregnant or nursing (lactating), women of child-bearing potential
without reliable contraception during the treatment and for at least 6 months after
the last dose.

- Patients who are protected adults under the terms of the law (French Public Health
Code).

- Refusal to consent.

- Patients for whom the diagnosis of HHT has not been confirmed clinically and / or by
molecular biology study.

- Active infection and/or fever>38°C

- Participation in another clinical trial within 28 days prior to inclusion.

- Hypersensitivity to the active substance or to any of the excipients.

- Known hypersensitivity to products of Chinese hamster ovary cells (CHO) or other
recombinant human or humanized antibodies.

- Patients who have taken Avastin ® intravenously in the 6 months prior to inclusion.

- Patients who have had a therapeutic endoscopy for gastrointestinal bleeding or ENT
surgery for epistaxis will have to wait at least 3 months less after treatment to be
included if bleeding persists.

- Patients who had a surgery in the month prior inclusion or planned surgery within 6
months

- Severe peripheral arterial disease with ulcerations

- Unhealed wound

- Thrombosis in the 6 months prior to inclusion

- Anticoagulant treatment

- Uncontrolled high blood pressure



Age minimum: 18 Years
Age maximum: N/A
Gender: All
Health Condition(s) or Problem(s) studied
Telangiectasia, Hereditary Hemorrhagic
Rendu Osler Disease
Intervention(s)
Drug: Bevacizumab
Drug: sodium chloride 0.9%
Primary Outcome(s)
number of red blood cell transfusions [Time Frame: 6 months]
Secondary Outcome(s)
digestive vascular malformations [Time Frame: 6 months]
epistaxis frequency [Time Frame: 3 months before treatment up to 6 months from the inclusion]
quality of life (SF36). [Time Frame: 3 months]
severity epistaxis score (ESS). [Time Frame: 6 months.]
hemoglobin [Time Frame: 3 months]
quality of life (SF36). [Time Frame: 6 months]
To evaluate pharmacokinetics of bevacizumab dose [Time Frame: 2 hours after the first treatment infusion]
adverse events [Time Frame: up to 6 months]
severity epistaxis score (ESS). [Time Frame: 3 months]
hemoglobin [Time Frame: 6 months]
To evaluate pharmacokinetics of bevacizumab dose [Time Frame: Before each 6 infusions]
duration of nosebleeds [Time Frame: 3 months before treatment up to 6 months from the inclusion]
Secondary ID(s)
2017-001031-39
69HCL17_0018
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey